William Blair analyst Matt Larew has maintained their bullish stance on ATR stock, giving a Buy rating on October 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors that suggest AptarGroup’s potential for future growth despite recent mixed results. The company has demonstrated resilience with its 10th consecutive EBITDA beat and 13th straight EPS beat, indicating strong operational performance. While there were some shortfalls in core sales and certain segments like consumer healthcare, the strength in injectables and the company’s ability to meet its guidance in all three segments for the upcoming quarter provide a positive outlook.
Furthermore, although the fourth-quarter EPS guidance was below consensus, the management’s commitment to achieving long-term growth targets in pharma, beauty, and closures segments reflects a strategic focus on overcoming current challenges. The stock’s current trading valuation suggests an opportunity for growth, supporting the Outperform rating. Overall, Larew’s analysis considers the company’s consistent performance and strategic initiatives as key drivers for recommending a Buy rating.
Larew covers the Healthcare sector, focusing on stocks such as AptarGroup, Thermo Fisher, and Option Care Health. According to TipRanks, Larew has an average return of 0.2% and a 47.76% success rate on recommended stocks.
In another report released on October 17, Raymond James also maintained a Buy rating on the stock with a $172.00 price target.